Patient-enabled Therapy for Advanced Parkinson’s Disease – A Case Study with Serina Therapeutics’ SER-252 + Enable Injections’ enFuse Wearable Drug Delivery Platform
Time: 10:45 am
day: Day 1
Details:
- SER-252 is a long-acting POZ-polymer conjugate of apomorphine, a potent dopamine agonist capable of treating the advanced stages of Parkinson's disease
- The enFuse Wearable Drug Delivery Platform allows for large volume administration (~ 25 mL) in the comfort of the patient's home, without the need for a healthcare provider to assist in delivery
- SER-252 + enFuse has entered IND-enabling studies and is on track to enter into a Phase I clinical trial in the 2H-2025